Search Results
The Vancouver Prostate Centre, Department of Urologic Sciences, 2660 Oak Street, Vancouver, British Columbia, Canada V6H‐3Z6
Search for other papers by Jennifer L Bishop in
Google Scholar
PubMed
The Vancouver Prostate Centre, Department of Urologic Sciences, 2660 Oak Street, Vancouver, British Columbia, Canada V6H‐3Z6
Search for other papers by Alastair Davies in
Google Scholar
PubMed
The Vancouver Prostate Centre, Department of Urologic Sciences, 2660 Oak Street, Vancouver, British Columbia, Canada V6H‐3Z6
Search for other papers by Kirsi Ketola in
Google Scholar
PubMed
The Vancouver Prostate Centre, Department of Urologic Sciences, 2660 Oak Street, Vancouver, British Columbia, Canada V6H‐3Z6
Search for other papers by Amina Zoubeidi in
Google Scholar
PubMed
Introduction Prostate cancer (PCa) has become the most common form of cancer in men in the developed world, and it ranks second in cancer-related deaths, with the vast majority of these fatalities resulting from metastatic disease ( Siegel et al
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Division of Bioinformatics, Walter and Eliza Hall Institute, Parkville, Victoria, Australia
Search for other papers by Stefano Mangiola in
Google Scholar
PubMed
Search for other papers by Ryan Stuchbery in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
Diagnostic Genomics, NICTA, Victoria Research Laboratory, The University of Melbourne, Parkville, Victoria, Australia
Search for other papers by Geoff Macintyre in
Google Scholar
PubMed
Search for other papers by Michael J Clarkson in
Google Scholar
PubMed
Search for other papers by Justin S Peters in
Google Scholar
PubMed
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia
Search for other papers by Anthony J Costello in
Google Scholar
PubMed
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia
Search for other papers by Christopher M Hovens in
Google Scholar
PubMed
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Urology, Frankston Hospital, Frankston, Victoria, Australia
Search for other papers by Niall M Corcoran in
Google Scholar
PubMed
Introduction Prostate cancer is the most widely diagnosed cancer among men in developed countries and the second most diagnosed cancer in men worldwide ( Torre et al . 2015 ). The widespread use of serum PSA measurement as an ad hoc community
Search for other papers by Tanya K Day in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories, School of Paediatrics and Reproductive Health, School of Agriculture, Discipline of Medicine, Hanson Institute, Adelaide Prostate Cancer Research Centre, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Tina Bianco-Miotto in
Google Scholar
PubMed
Introduction Numerous diseases are associated with abnormal hormonal regulation including breast and prostate cancers. Breast cancer is a heterogeneous disease that can be classified in many ways. The most primary classification is by hormone
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Stefan J Barfeld in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Harri M Itkonen in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Alfonso Urbanucci in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Prostate Cancer Research Group Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Prostate Cancer Research Group Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Ian G Mills in
Google Scholar
PubMed
) ( DeBerardinis et al . 2008 ). It is therefore not surprising that metabolic adaptations have been reported in various human cancers ( Hsu & Sabatini 2008 ). Metabolic status of the prostate gland and cancer predisposition The prostate gland is principally
Search for other papers by Douglas W Strand in
Google Scholar
PubMed
Search for other papers by Andrew S Goldstein in
Google Scholar
PubMed
. The regulation of these progenitors has been the subject of intense research and debate with implications for a wide range of diseases, including those of the prostate. Because of the resistance of prostate progenitor cells to current anti
Search for other papers by Hidewaki Nakagawa in
Google Scholar
PubMed
Introduction Prostate cancer (PC) is the most common malignancy in men and the second leading cause of cancer-related deaths in Western countries. Incidence and mortality rates vary widely across geographic regions and ethnic groups ( Gronberg 2003
Search for other papers by Su Liu in
Google Scholar
PubMed
Search for other papers by Shin-Jen Lin in
Google Scholar
PubMed
Search for other papers by Gonghui Li in
Google Scholar
PubMed
Search for other papers by Eungseok Kim in
Google Scholar
PubMed
Search for other papers by Yei-Tsung Chen in
Google Scholar
PubMed
Search for other papers by Dong-Rong Yang in
Google Scholar
PubMed
Search for other papers by M H Eileen Tan in
Google Scholar
PubMed
Search for other papers by Eu Leong Yong in
Google Scholar
PubMed
George Whipple Laboratory for Cancer Research, Department of Obstetrics and Gynecology, Chawnshang Chang Liver Cancer Center and Department of Urology, Department of Biological Sciences, Cardiovascular Research Institute, Sex Hormone Research Center, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
Search for other papers by Chawnshang Chang in
Google Scholar
PubMed
that inactivation of ARA55 inhibits the agonist effect of antiandrogens in prostate cancer (PCa) cells ( Rahman et al . 2003 ). Does increased TR4 activity induced by ARA55 inactivation play a role here? Further experiments are needed to answer this
Search for other papers by Alastair H Davies in
Google Scholar
PubMed
Vancouver Prostate Centre, Vancouver, British Columbia, Canada
Search for other papers by Amina Zoubeidi in
Google Scholar
PubMed
Introduction Prostate cancer was first identified by Adams in 1853. Adams noted that the condition was 'a very rare disease' ( Adams 1853 ). Prostate cancer has become one of the most common cancers in men: nearly 200,000 men are diagnosed
Search for other papers by Maho Shibata in
Google Scholar
PubMed
Search for other papers by Michael M Shen in
Google Scholar
PubMed
Introduction For the past 70 years, androgen-deprivation therapy has remained the mainstay of treatment for prostate cancer. Although most prostate cancers initially respond to androgen deprivation, many will ultimately progress to lethal castration
Search for other papers by Amina Zoubeidi in
Google Scholar
PubMed
Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California, USA
Department of Veterans Affairs, Northern California Health Care System, Mather, California, USA
Search for other papers by Paramita M Ghosh in
Google Scholar
PubMed
Introduction Localized prostate cancer can be treated with surgery; however, metastasized prostate cancer is usually treated with hormonal ablation. Improved diagnostic tools and earlier diagnosis has helped increase the 10-year survival of